CD19 and leukemia: In in vivo studies, 1928zT2 T cells demonstrated more effective elimination of CD19+ leukemia cells, reduced tumor burden, and prolonged survival in leukemia models (cell line-derived xenografts and patient-derived xenograft models); meanwhile, m28zT2 T cells could shrink mesothelin+ solid tumors and inhibit tumor metastasis in solid tumor models—whereas conventional m28z T cells led to increased tumor burden in metastatic models.